|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-2-17
|
|
pubmed:abstractText |
Sunitinib is standard first-line therapy for metastatic clear cell renal cancer (MCRC). It is associated with leucopenia; however, its effects on specific immune cell subsets are unclear. Alterations in immune cell subsets may contribute to tumour progression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1423-0399
|
|
pubmed:author |
pubmed-author:AugwalSamirS,
pubmed-author:BoletiKatiaK,
pubmed-author:BowerMarkM,
pubmed-author:ChowdhurySimonS,
pubmed-author:GreenJamesJ,
pubmed-author:LimLouiseL,
pubmed-author:PetersJohnJ,
pubmed-author:PowlesThomasT,
pubmed-author:SadevAnjuA,
pubmed-author:SarwarNaveedN,
pubmed-author:SaundersNataileN,
pubmed-author:ShamashJonathanJ
|
|
pubmed:copyrightInfo |
Copyright © 2010 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
53-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20975250-Aged,
pubmed-meshheading:20975250-Antineoplastic Agents,
pubmed-meshheading:20975250-Carcinoma, Renal Cell,
pubmed-meshheading:20975250-Female,
pubmed-meshheading:20975250-Humans,
pubmed-meshheading:20975250-Indoles,
pubmed-meshheading:20975250-Kidney Neoplasms,
pubmed-meshheading:20975250-Lymphocytes,
pubmed-meshheading:20975250-Male,
pubmed-meshheading:20975250-Middle Aged,
pubmed-meshheading:20975250-Neoplasm Metastasis,
pubmed-meshheading:20975250-Pyrroles,
pubmed-meshheading:20975250-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.
|
|
pubmed:affiliation |
St Bartholomew Hospital, London, UK. thomas.powles@bartsandthelondon.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
